查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2150660

Sirna製藥市場報告：趨勢、預測和競爭分析（至2035年）

Sirna Drug Market Report: Trends, Forecast and Competitive Analysis to 2035
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

siRNA藥物市場

全球siRNA藥物市場前景廣闊，醫院、研究機構以及製藥和生物技術公司都將從中受益。預計全球siRNA藥物市場規模將從2027年的24億美元成長至2035年的107億美元，2027年至2035年的複合年成長率（CAGR）為19.4%。推動該市場成長的關鍵因素包括遺傳性疾病盛行率的上升、個人化醫療需求的成長以及人們對RNA療法的日益關注。

  • 根據 Lucintel 的預測，由於奈米顆粒在細胞內遞送方面具有卓越的效率和穩定性，預計在預測期內，奈米顆粒在遞送方式類別中將呈現最高的成長率。
  • 在終端用戶類別中，鑑於基因靜默療法的臨床應用日益廣泛，預計醫院產業在整個預測期內將呈現最高的成長速度。
  • 從區域來看，由於研發能力的增強以及生物技術和基因治療產業的建立，預計北美在預測期內將呈現最高的成長率。

siRNA藥物市場的新趨勢

siRNA藥物市場正從早期平台階段發展到成熟藥物階段。預計在2025年至2027年間，藥物遞送系統的改進和商業性合作的增加將加速罕見疾病、心血管和代謝疾病以及感染疾病藥物的研發。據Lucintel公司稱，藥物遞送平台的成熟度將決定市場長期永續成長的潛力。

  • 精準治療：到2025年，多種針對基因組異常疾病的siRNA藥物將進入後期臨床開發階段。 RNAi藥物傳遞和生產技術的改進，以及對臨床終點更深入的理解，將使製藥公司能夠專注於罕見疾病領域。
  • 標靶遞送：利用 GalNAc 綴合物將 siRNA 藥物遞送至肝臟仍是該領域的主要研究方向。然而，將 siRNA 藥物遞送至其他組織（肝臟以外）的技術改進有望加速新適應症的藥物研發。預計到 2025 年，非肝臟組織的遞送效率將得到提升，這激發了人們對先前未開發領域的進一步研究。
  • 拓展至慢性疾病領域：各公司正將siRNA療法的研發重點從罕見疾病轉向更常見的心血管代謝疾病。雖然較大的患者族群能夠提升療法的商業性潛力，但治療方案的成本和療效仍將影響其市場前景。
  • 生產能力提升：領先的寡核苷酸生產商已投資於製程和設備，以提高其在2025年前生產千噸批次產品的能力。寡核苷酸合成和純化技術的進步提高了批次一致性，並保障了治療批次的供應。寡核苷酸療法生產能力的提升可望降低單次給藥成本。
  • 基於合作的策略：合作仍然是商業性展示RNA技術的主要方式，尤其對於缺乏全球商業化能力的公司更是如此。風險分擔和地理限制的權利設定影響了2025年的合作模式。未來五年，合作預計將透過控制對專用遞送系統的使用，對RNA技術市場產生影響。

RNA療法的生產能力和穩定性將成為市場競爭的關鍵差異化因素。預計夥伴關係關係的競爭將加劇。能夠將RNA療法生產能力與可靠的供應鏈和緩衝機制結合的公司，將更有利於建立RNA療法的商業性夥伴關係。

siRNA藥物市場的最新趨勢

隨著更多藥物上市以及製藥公司開發藥物遞送系統，siRNA藥物市場預計將在2025年至2027年間持續成長。據Lucintel公司稱，許多核准藥物將靶向肝臟，需要重複給藥。投資者已開始為siRNA藥物公司提供資金，並且越來越多的商業性合作關係正在形成。

  • FDA擴大siRNA藥物的適應症：2025年3月，FDA核准Qfitlia用於治療部分A型和B型血友病患者。此核准擴大了siRNA藥物的適用範圍，使其涵蓋血脂異常症患者以及非移植族群。
  • siRNA 藥物在心血管疾病中的應用：同樣在 2025 年 3 月，「Amvuttra」獲得了 FDA 的批准，擴大了其治療選擇範圍，使其涵蓋患有特定心血管疾病的患者。
  • 策略聯盟：2025年，Alnilam Pharmaceuticals宣布擴大與Regeneron Pharmaceuticals的現有合作關係，共同發現並開發RNAi療法。該聯盟將降低Alnilam在發現和開發RNAi療法方面面臨的風險。
  • 擴大生產規模：Alnilam預計到2025年需要2億美元的資金來擴大其RNAi產品供應鏈。每種商業化產品預計可提供數十萬劑。雖然Alnilam尚未披露具體的產能目標，但該公司預計競爭對手的偶聯物供應將成為市場擴張的阻礙因素。
  • 產品線多元化：Silence Therapeutics計畫於2025年拓展其GalNAc-siRNA產品線，將心血管和代謝標靶治療納入其中。該公司選擇的遞送系統必須能夠應對其平台能否解決系統性病理的挑戰。

Alnilam 和 Silence 預計，各自市場的主要阻礙因素將在於給藥技術而非生物學。心血管和代謝適應症領域的競爭將異常激烈。先發優勢可能只是暫時的，尤其是在這些系統適用於多種疾病的情況下。生產限制和產能將影響適應症策略以及醫療保健計劃實施的定價和報銷政策。

目錄

第1章：執行摘要

第2章 市場概覽

  • 背景與分類
  • 供應鏈

第3章 市場趨勢與預測分析

  • 宏觀經濟趨勢與預測
  • 產業促進因素與挑戰
  • PESTLE分析
  • 專利分析
  • 法規環境

第4章：全球Sirna藥物市場：依給藥途徑分類

  • 吸引力分析：以配送方式
  • 奈米顆粒
  • 脂質系統
  • 聚合物體系
  • 其他

第5章：全球Sirna藥物市場：按應用領域分類

  • 吸引力分析：依目的
  • 腫瘤學
  • 心血管系統
  • 呼吸系統
  • 神經系統
  • 感染疾病
  • 其他

第6章：全球Sirna製藥市場：依最終用途分類

  • 吸引力分析：依最終用途分類
  • 醫院
  • 研究機構
  • 製藥和生物技術公司
  • 其他

第7章 區域分析

第8章：北美西納製藥市場

  • 北美siRNA藥物市場：依給藥途徑分類
  • 北美siRNA藥物市場：按應用領域分類
  • 美國西爾納製藥市場
  • 加拿大Sirna製藥市場
  • 墨西哥的Sirna製藥市場

第9章：歐洲西爾納製藥市場

  • 歐洲siRNA藥物市場：依給藥途徑分類
  • 歐洲siRNA藥物市場：按應用領域分類
  • 德國西爾納製藥市場
  • 法國西爾納製藥市場
  • 義大利Sirna製藥市場
  • 西班牙Sirna製藥市場
  • 英國Sirna製藥市場

第10章：亞太地區的Sirna製藥市場

  • 亞太地區siRNA藥物市場：依給藥方式分類
  • 亞太地區siRNA藥物市場：依最終用途分類
  • 中國西爾納製藥市場
  • 印度Sirna製藥市場
  • Sirna製藥的日本市場
  • 韓國Sirna製藥市場
  • 印尼Sirna製藥市場

第11章：西爾納藥品市場

  • 其他區域 siRNA 藥物市場：依給藥方式分類
  • 其他區域 siRNA 藥物市場：依最終用途分類
  • 中東的Sirna製藥市場
  • 南美Sirna製藥市場
  • 非洲西爾納製藥市場

第12章 競爭分析

  • 產品系列分析
  • 業務整合
  • 波特五力分析
  • 市佔率分析

第13章 機會與策略分析

  • 價值鏈分析
  • 成長機會分析
  • 新趨勢：全球Sirna製藥市場
  • 戰略分析

第14章：價值鏈中關鍵企業的公司概況

  • 競爭分析概述
  • Alnylam Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Silence Therapeutics plc
  • Dicerna Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Benitec Biopharma Ltd.
  • Marina Biotech, Inc.
  • Quark Pharmaceuticals, Inc.
  • RXi Pharmaceuticals Corporation

第15章附錄

Sirna Drug Market

The future of the global sirna drug market looks promising with opportunities in the hospital, research institute, and pharmaceutical & biotechnology company markets. The global sirna drug market is expected to reach an estimated $10.7 billion by 2035 from $2.4 billion in 2027 with a CAGR of 19.4% from 2027 to 2035. The major drivers for this market are the increasing prevalence of genetic disorders, the rising demand for personalized medicine, and the growing focus on RNA-based therapies.

  • Lucintel forecasts that, within the delivery method category, nanoparticles is expected to witness the highest growth over the forecast period due to better cellular delivery and stability offered by nanoparticles.
  • Within the end use category, hospitals is expected to witness the highest growth over the forecast period due to increased clinical use of gene silencing therapies.
  • In terms of regions, North America is expected to witness the highest growth over the forecast period due to strengthened research and well-established biotechnology and gene therapy industries.

Emerging Trends in Sirna Drug Market

The market for siRNA drugs is evolving from early-stage platforms to established drugs. During the 2025-2027 time period, we expect better delivery systems and more commercial partnerships to accelerate the development of drugs for rare diseases, cardiovascular and metabolic conditions, and infectious diseases. According to Lucintel, the maturity of drug delivery platforms determines the potential for longer-term, sustainable market growth.

  • Precision Therapeutics: In 2025, several siRNA drugs targeting diseases caused by genomic abnormalities progressed to advanced stages of clinical development. Improvements in RNAi drug delivery and manufacturing, along with better understanding of the clinical endpoints, should allow drug developers to focus on less common diseases.
  • Targeted Delivery: Delivery of siRNA drugs to the liver using GalNAc conjugates continues to be the primary focus of the field; however, improvements in the delivery of siRNA drugs to other (extricate) tissues could stimulate the development of drugs for new indications. Increased delivery efficiency to extricate tissues in 2025 encouraged further research in previously unexplored areas.
  • Expansion Into Chronic Diseases: Companies are shifting siRNA therapy development from targeting ultra-rare diseases to more prevalent cardiometabolic disorders. While larger patient populations enhance the commercial potential of a therapy, the cost and efficacy of therapeutic approaches will impact the market potential.
  • Advances in Manufacturability: Leading oligonucleotide manufacturers made process and facilities investments in 2025 to improve their capacity to produce kilogram-scale batches. Advances in synthesis and purification of oligonucleotides have improved the consistency of batches and the supply of therapeutic batches. Improved manufacturability of oligonucleotide therapies should decrease the cost of each dose.
  • Alliance-based Strategies: Alliances remain the predominant method to commercially validate RNA-based technologies, particularly for companies lacking the ability to commercialize on a global scale. Shared risks and limited geographic-based rights influenced 2025 alliances. In the next five years, alliances will impact the RNA technology market by controlling access to specialized delivery systems.

Manufacturing and durability of RNA therapies will be the primary competitive differentiators in the market. Competition will intensify for allied partnerships. Companies that integrate manufacturability of RNA therapies with reliable supply and cushioning will be best positioned to achieve commercial partnerships for RNA therapies.

Recent Developments in the Sirna Drug Market

The market for siRNA drugs is anticipated to grow between the years 2025 and 2027, as more drugs come to market and medical companies build their delivery systems. According to Lucintel, more approved drugs will target the liver and induce the need for repeat medication. Investors have begun to fund siRNA drug companies, and more commercial partnerships have formed.

  • The FDA's Expansion of The Use of SiRNA Drugs: In March 2025, the FDA approved Qfitlia to treat certain patients with haemophilia A and B. With this approval, the use of siRNA drugs to treat patients outside of the lipid disorders and deployments market has expanded.
  • Use of SiRNA Drugs in Cardiovascular: Also in March 2025, Amvuttra received FDA approval and was expanded to treat certain patients with cardiovascular disease.
  • Strategic Alliances: In 2025, Alnylam Pharmaceuticals, Inc. announced an expansion to its existing partnership with Regeneron Pharmaceuticals, Inc. to jointly discover and develop RNAi therapeutics. This alliance reduces the risk for Alnylam for the discovery and development of RNAi therapeutics.
  • Manufacturing Scale-up: Alnylam projected a need for $200 million in 2025 to build out RNAi product supply. Each commercial product is expected to facilitate hundreds of thousands of doses. While Alnylam is not publicly stating specific capacity goals, Alnylam expects rival supply of conjugates to be a binding constraint for market expansion.
  • Pipeline Diversification: Silence Therapeutics added to its GalNAc-siRNA pipeline in 2025 to include the cardiovascular and metabolic systems. The company's choice of delivery systems will have to address whether the platform is capable of addressing system level pathology.

Alnylam and Silence expect the dominant constraints on their markets to be the science of delivery and not the biology. Competition will be fierce for cardiovascular and metabolic labels. The first-mover advantage may be short-lived, especially if the systems can be applied to the broad array of pathologies. Manufacturing constraints and capacity will influence the labelling strategy and the pricing and reimbursement policies implemented by healthcare systems.

Strategic Growth Opportunities in the Sirna Drug Market

The commercialization of siRNA drugs is expected to increase due to several recent developments. Lowering barriers to adoption will encourage the sale of siRNA drugs. Between 2024 and 2026, expected approvals will increase and provide therapies for non-rare, or chronic, diseases. We've defined five of these developments and expect they will influence strategic alliances and investment in the coming years.

  • Cardiometabolic Therapies: In March 2025, the FDA approved Fitusiran for the treatment of haemophilia. Metabolic conditions and other cardiovascular diseases are expected to benefit from siRNA therapy in the next 3 to 5 years.
  • Premium Long-Acting Therapies: Alnylam said that 2 million doses of the drug ONPATTRO and AMVUTTRA had been administered as of June 2025. Premium prices can be charged for long-acting therapies.
  • International Markets: In 2025, China approved the first siRNA drug, patisiran. Other countries in the Asia-Pacific region are expected to follow China's lead, as there is sufficient capacity and demand for these specialty drugs.
  • Advancements in Manufacturability: Contract manufacturers are partnering with companies to produce siRNAs using higher-yield processes. An industry report predicted that there will be over 20 siRNA candidates in clinical development by 2025. Improvements in manufacturing processes will improve industry profit margins in the upcoming years.
  • Alternative Delivery Systems: GalNAc is currently the dominant delivery system for targeting the liver. However, other systems are being developed for targeting other areas of the CNS and the muscle. In 2025, Alnylam announced that their drug in development for the liver, zilebesiran, met its primary endpoint in its Phase 3 clinical trial.

Delivering therapeutic siRNAs remains the biggest challenge for the siRNA companies. There is potential for significant market opportunities for siRNA-based medicines in various indications, especially if they are priced based on the evidence supporting the Medicare reimbursement. The greatest opportunity is for medicines that provide durable replacements for chronic, symptomatic conditions.

Sirna Drug Market Drivers and Challenges

Technological developments such as the simplification of siRNA production and synthesis and advancements in drug formulation and delivery systems, combined with the development of favorable regulations and reimbursement policies and the increase in investment in life sciences, create opportunities for the growth of the sirna drug market. Risks include the high costs of clinical development, access and reimbursement. The pace of development and commercial launch of siRNA drugs will be determined by the balance of these factors.

The factors responsible for driving this market include:

  • Increasing Demand for Personalized Medicine: With more targeted therapies becoming available for rare cancers, and with recently approved siRNA therapies to treat rare diseases such as transthyretin-related amyloidosis, the enzyme Reactive LDL Cholesterolaemia, and Lipoprotein, and Hepatocytic Porphyrius, the number of indications for siRNA therapeutics is anticipated to rapidly increase. The positive clinical outcomes of siRNA drugs will encourage demand for other lasting and precise therapies in the field of oncology, cardiology, metabolic disorders, and other field of medicine. It is anticipated that in the next five years, the personalized medicine industry will flourish.
  • Advances in Delivery Technologies: Modifications to siRNA delivery technologies including the use of lipid nanoparticles and GalNAc conjugation, as well as the development of tissue-targeted delivery systems, are improving the stability and increasing the duration of action of siRNA. GalNAc-based therapies approved in 2025 allowed for dose intervals of approximately six months. In the next several years, the technologies are likely to allow for the targeting and treatment of a variety of neurological, pulmonary, and systemic diseases.
  • Regulatory Updates and Clinical Advances: The favorable decisions by regulatory agencies on siRNA-based therapies and the increasing number of clinical trials positively influenced the market perception of siRNA. In 2025, there was expected to be a consistent body of evidence supporting the safety and efficacy of multiple siRNA therapies for the treatment of rare and chronic diseases. The improvement and clarification of regulatory pathways and the body of clinical evidence is expected to result in the formation of new strategic alliances to advance and support the further development of late stage siRNA therapies.
  • Addressing Chronic Disease Indications: SiRNA therapies are being developed for conditions where there is benefit from reducing the level of a particular protein, including transthyretin mediated amyloidosis (TMA) and other genetic and liver diseases, as well as conditions such as hypertension and hypercholesterolemia. Therapies targeting chronic indications are being evaluated using three to twelve month dosing. Continuous improvements in siRNA technology are expected to create a market characterized by a few, high-value, rapidly repeating revenue streams.
  • Manufacturing Efficiency and Platform Investment: The barriers to production of siRNA therapies have lessened due to a variety of reasons including improvements in large-scale manufacturing and automation. In June 2025, companies disclosed the use of automated platforms to manufacture siRNA at a large scale. In the next 3-5 years, further process improvements are expected to ease the supply constraints for siRNA therapies. As a result, price reductions are expected.

The challenges facing this market include:

  • Delivery and Tissue Targeting: Most of the currently available siRNA therapies target the liver. The brain, muscles, and other tissues remain inaccessible. To reach previously untargeted tissues, there is ongoing research to develop new delivery systems. This affects the market because untargeted tissues equal a lack of therapies for those diseases and increases the market risk.
  • Safety and Immune Response: SiRNA therapies are known to cause unwanted side effects and reduce the duration of treatment. In August 2025, studies assessed the long-term effects of siRNA therapy. Improving the duration of action of siRNA therapies and reducing side effects is essential for the market to grow.
  • High Costs and Uncertain Reimbursement: Therapies may cost a lot to research and develop because they may require specialized manufacturing, long-term and continuous monitoring, and other post-marketing requirements. In 2025, the expected annual cost of some RNA therapies was estimated to be more than $100,000. The high costs of some innovative therapies will potentially result in insurers restricting coverage to only the most serious cases and requiring clinical and economic evidence to prove that the therapy will yield better outcomes than other available therapies.

Advances in the delivery of siRNA drugs, and an improving regulatory environment, should stimulate the market for siRNA drugs. Interest in the treatment of chronic and rare diseases is expected to improve the market. However, several factors, including high costs, may impact the success of drugs in the market and the pipelines of pharmaceutical companies. Improvements in the safety and affordability of therapies are likely to benefit the most the number of patients suffering from chronic and rare diseases.

List of Sirna Drug Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies sirna drug market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the sirna drug market companies profiled in this report include-

  • Alnylam Pharmaceuticals, Inc.
  • Arrowhead Pharmaceuticals, Inc.
  • Silence Therapeutics plc
  • Dicerna Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Benitec Biopharma Ltd.
  • Marina Biotech, Inc.
  • Quark Pharmaceuticals, Inc.
  • RXi Pharmaceuticals Corporation

Sirna Drug Market by Segment

The study includes a forecast for the global sirna drug market by delivery method, application, end use, and region.

Sirna Drug Market by Delivery Method [Value ($B) from 2019 to 2035]:

  • Nanoparticles
  • Lipid-based
  • Polymer-based
  • Others

Sirna Drug Market by Application [Value ($B) from 2019 to 2035]:

  • Oncology
  • Cardiovascular
  • Respiratory
  • Neurological
  • Infectious Diseases
  • Others

Sirna Drug Market by End Use [Value ($B) from 2019 to 2035]:

  • Hospitals
  • Research Institutes
  • Pharmaceutical & Biotechnology Companies
  • Others

Sirna Drug Market by Region [Value ($B) from 2019 to 2035]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Sirna Drug Market

The scope of the sirna drug market has begun to evolve, focusing on cardiovascular and metabolic disorders, as well as diseases of the liver. It is expected that by 2025-2027 the market will be more widely established due to the anticipated approval of siRNA drugs, as well as on-site manufacturing and licensing. The rest of the market will be determined by the skills of market players to manufacture and distribute drugs, and their ability to negotiate insurance reimbursement. According to Lucintel, the sirna drug market is still in its early stages and evolving.

  • United States: In March 2025, the FDA approved Alnylam's Qfitlia (fitusiran) for the treatment of haemophilia A and B. The approval advanced the RNA Interference ('RNAi') drug development platform and encouraged the development of drugs to treat other disorders. Other drugs in this class may be approved in the next 3-5 years.
  • China: In 2025, Alnylam received approval from the NMPA to market vutrisiran for the treatment of hereditary transthyretin-related amyloidosis. China's first approval of an siRNA drug established a pathway for Alnylam to commercialize its drugs in the Chinese market and encouraged other pharmaceutical companies to pursue siRNA drug development.
  • Germany: Although European approval processes enabled the local distribution of approved siRNA products, German pharmaceutical companies continued to work on RNA and sterile injectable products. Where Germany stands in the high-quality biologics market in the next few years will determine the potential supply of these products.
  • India: In addition to its collaboration to provide specialty medicines, Cipla strengthened its partnerships to provide innovative medicines. Indian regulators and biopharmaceutical companies began preparing for the introduction of RNA therapies, which are expected to be available commercially from 2025. India has the potential to produce therapies at a lower cost, and if successful, meet the demand within the country and export to other regions.
  • Japan: Newer RNA-based therapies for various rare diseases are expected to be approved. In addition to its programs to facilitate the approval of new rare disease therapies, Japan's national health insurance system and reimbursement policies strengthened the commercial potential of RNA therapies.

Features of the Global Sirna Drug Market

  • Market Size Estimates: sirna drug market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
  • Segmentation Analysis: sirna drug market size by delivery method, application, end use, and region in terms of value ($B).
  • Regional Analysis: sirna drug market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different delivery method, application, end use, and regions for the sirna drug market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the sirna drug market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the sirna drug market by delivery method (nanoparticles, lipid-based, polymer-based, and others), application (oncology, cardiovascular, respiratory, neurological, infectious diseases, and others), end use (hospitals, research institutes, pharmaceutical & biotechnology companies, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global siRNA Drug Market by Delivery Method

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Delivery Method
  • 4.3 Nanoparticles : Trends and Forecast 2019 to 2035
  • 4.4 Lipid-based : Trends and Forecast 2019 to 2035
  • 4.5 Polymer-based : Trends and Forecast 2019 to 2035
  • 4.6 Others : Trends and Forecast 2019 to 2035

5. Global siRNA Drug Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Oncology : Trends and Forecast 2019 to 2035
  • 5.4 Cardiovascular : Trends and Forecast 2019 to 2035
  • 5.5 Respiratory : Trends and Forecast 2019 to 2035
  • 5.6 Neurological : Trends and Forecast 2019 to 2035
  • 5.7 Infectious Diseases : Trends and Forecast 2019 to 2035
  • 5.8 Others : Trends and Forecast 2019 to 2035

6. Global siRNA Drug Market by End Use

  • 6.1 Overview
  • 6.2 Attractiveness Analysis by End Use
  • 6.3 Hospitals : Trends and Forecast 2019 to 2035
  • 6.4 Research Institutes : Trends and Forecast 2019 to 2035
  • 6.5 Pharmaceutical & Biotechnology Companies : Trends and Forecast 2019 to 2035
  • 6.6 Others : Trends and Forecast 2019 to 2035

7. Regional Analysis

  • 7.1 Overview
  • 7.2 Global siRNA Drug Market by Region

8. North American siRNA Drug Market

  • 8.1 Overview
  • 8.2 North American siRNA Drug Market by Delivery Method
  • 8.3 North American siRNA Drug Market by End Use
  • 8.4 The United States siRNA Drug Market
  • 8.5 Canadian siRNA Drug Market
  • 8.6 Mexican siRNA Drug Market

9. European siRNA Drug Market

  • 9.1 Overview
  • 9.2 European siRNA Drug Market by Delivery Method
  • 9.3 European siRNA Drug Market by End Use
  • 9.4 German siRNA Drug Market
  • 9.5 French siRNA Drug Market
  • 9.6 Italian siRNA Drug Market
  • 9.7 Spanish siRNA Drug Market
  • 9.8 The United Kingdom siRNA Drug Market

10. APAC siRNA Drug Market

  • 10.1 Overview
  • 10.2 APAC siRNA Drug Market by Delivery Method
  • 10.3 APAC siRNA Drug Market by End Use
  • 10.4 Chinese siRNA Drug Market
  • 10.5 Indian siRNA Drug Market
  • 10.6 Japanese siRNA Drug Market
  • 10.7 South Korean siRNA Drug Market
  • 10.8 Indonesian siRNA Drug Market

11. ROW siRNA Drug Market

  • 11.1 Overview
  • 11.2 ROW siRNA Drug Market by Delivery Method
  • 11.3 ROW siRNA Drug Market by End Use
  • 11.4 Middle Eastern siRNA Drug Market
  • 11.5 South American siRNA Drug Market
  • 11.6 African siRNA Drug Market

12. Competitor Analysis

  • 12.1 Product Portfolio Analysis
  • 12.2 Operational Integration
  • 12.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 12.4 Market Share Analysis

13. Opportunities & Strategic Analysis

  • 13.1 Value Chain Analysis
  • 13.2 Growth Opportunity Analysis
    • 13.2.1 Growth Opportunity by Delivery Method
    • 13.2.2 Growth Opportunity by Application
    • 13.2.3 Growth Opportunity by End Use
  • 13.3 Emerging Trends in the Global siRNA Drug Market
  • 13.4 Strategic Analysis
    • 13.4.1 New Product Development
    • 13.4.2 Certification and Licensing
    • 13.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

14. Company Profiles of the Leading Players Across the Value Chain

  • 14.1 Competitive Analysis Overview
  • 14.2 Alnylam Pharmaceuticals, Inc.
    • Company Overview
    • siRNA Drug Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.3 Arrowhead Pharmaceuticals, Inc.
    • Company Overview
    • siRNA Drug Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.4 Silence Therapeutics plc
    • Company Overview
    • siRNA Drug Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.5 Dicerna Pharmaceuticals, Inc.
    • Company Overview
    • siRNA Drug Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.6 Ionis Pharmaceuticals, Inc.
    • Company Overview
    • siRNA Drug Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.7 Arbutus Biopharma Corporation
    • Company Overview
    • siRNA Drug Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.8 Benitec Biopharma Ltd.
    • Company Overview
    • siRNA Drug Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.9 Marina Biotech, Inc.
    • Company Overview
    • siRNA Drug Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.10 Quark Pharmaceuticals, Inc.
    • Company Overview
    • siRNA Drug Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 14.11 RXi Pharmaceuticals Corporation
    • Company Overview
    • siRNA Drug Market Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

15. Appendix

  • 15.1 List of Figures
  • 15.2 List of Tables
  • 15.3 Research Methodology
  • 15.4 Disclaimer
  • 15.5 Copyright
  • 15.6 Abbreviations and Technical Units
  • 15.7 About Us
  • 15.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global siRNA Drug Market
  • Figure 2.1: Usage of siRNA Drug Market
  • Figure 2.2: Classification of the Global siRNA Drug Market
  • Figure 2.3: Supply Chain of the Global siRNA Drug Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 3.19: Driver and Challenges of the siRNA Drug Market
  • Figure 4.1: Global siRNA Drug Market by Delivery Method in 2019, 2026, and 2035
  • Figure 4.2: Trends of the Global siRNA Drug Market ($B) by Delivery Method
  • Figure 4.3: Forecast for the Global siRNA Drug Market ($B) by Delivery Method
  • Figure 4.4: Trends and Forecast for Nanoparticles in the Global siRNA Drug Market (2019-2035)
  • Figure 4.5: Trends and Forecast for Lipid-based in the Global siRNA Drug Market (2019-2035)
  • Figure 4.6: Trends and Forecast for Polymer-based in the Global siRNA Drug Market (2019-2035)
  • Figure 4.7: Trends and Forecast for Others in the Global siRNA Drug Market (2019-2035)
  • Figure 5.1: Global siRNA Drug Market by Application in 2019, 2026, and 2035
  • Figure 5.2: Trends of the Global siRNA Drug Market ($B) by Application
  • Figure 5.3: Forecast for the Global siRNA Drug Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Oncology in the Global siRNA Drug Market (2019-2035)
  • Figure 5.5: Trends and Forecast for Cardiovascular in the Global siRNA Drug Market (2019-2035)
  • Figure 5.6: Trends and Forecast for Respiratory in the Global siRNA Drug Market (2019-2035)
  • Figure 5.7: Trends and Forecast for Neurological in the Global siRNA Drug Market (2019-2035)
  • Figure 5.8: Trends and Forecast for Infectious Diseases in the Global siRNA Drug Market (2019-2035)
  • Figure 5.9: Trends and Forecast for Others in the Global siRNA Drug Market (2019-2035)
  • Figure 6.1: Global siRNA Drug Market by End Use in 2019, 2026, and 2035
  • Figure 6.2: Trends of the Global siRNA Drug Market ($B) by End Use
  • Figure 6.3: Forecast for the Global siRNA Drug Market ($B) by End Use
  • Figure 6.4: Trends and Forecast for Hospitals in the Global siRNA Drug Market (2019-2035)
  • Figure 6.5: Trends and Forecast for Research Institutes in the Global siRNA Drug Market (2019-2035)
  • Figure 6.6: Trends and Forecast for Pharmaceutical & Biotechnology Companies in the Global siRNA Drug Market (2019-2035)
  • Figure 6.7: Trends and Forecast for Others in the Global siRNA Drug Market (2019-2035)
  • Figure 7.1: Trends of the Global siRNA Drug Market ($B) by Region (2019-2026)
  • Figure 7.2: Forecast for the Global siRNA Drug Market ($B) by Region (2027-2035)
  • Figure 8.1: Trends and Forecast for the North American siRNA Drug Market (2019-2035)
  • Figure 8.2: North American siRNA Drug Market by Delivery Method in 2019, 2026, and 2035
  • Figure 8.3: Trends of the North American siRNA Drug Market ($B) by Delivery Method (2019-2026)
  • Figure 8.4: Forecast for the North American siRNA Drug Market ($B) by Delivery Method (2027-2035)
  • Figure 8.5: North American siRNA Drug Market by Application in 2019, 2026, and 2035
  • Figure 8.6: Trends of the North American siRNA Drug Market ($B) by Application (2019-2026)
  • Figure 8.7: Forecast for the North American siRNA Drug Market ($B) by Application (2027-2035)
  • Figure 8.8: North American siRNA Drug Market by End Use in 2019, 2026, and 2035
  • Figure 8.9: Trends of the North American siRNA Drug Market ($B) by End Use (2019-2026)
  • Figure 8.10: Forecast for the North American siRNA Drug Market ($B) by End Use (2027-2035)
  • Figure 8.11: Trends and Forecast for the United States siRNA Drug Market ($B) (2019-2035)
  • Figure 8.12: Trends and Forecast for the Mexican siRNA Drug Market ($B) (2019-2035)
  • Figure 8.13: Trends and Forecast for the Canadian siRNA Drug Market ($B) (2019-2035)
  • Figure 9.1: Trends and Forecast for the European siRNA Drug Market (2019-2035)
  • Figure 9.2: European siRNA Drug Market by Delivery Method in 2019, 2026, and 2035
  • Figure 9.3: Trends of the European siRNA Drug Market ($B) by Delivery Method (2019-2026)
  • Figure 9.4: Forecast for the European siRNA Drug Market ($B) by Delivery Method (2027-2035)
  • Figure 9.5: European siRNA Drug Market by Application in 2019, 2026, and 2035
  • Figure 9.6: Trends of the European siRNA Drug Market ($B) by Application (2019-2026)
  • Figure 9.7: Forecast for the European siRNA Drug Market ($B) by Application (2027-2035)
  • Figure 9.8: European siRNA Drug Market by End Use in 2019, 2026, and 2035
  • Figure 9.9: Trends of the European siRNA Drug Market ($B) by End Use (2019-2026)
  • Figure 9.10: Forecast for the European siRNA Drug Market ($B) by End Use (2027-2035)
  • Figure 9.11: Trends and Forecast for the German siRNA Drug Market ($B) (2019-2035)
  • Figure 9.12: Trends and Forecast for the French siRNA Drug Market ($B) (2019-2035)
  • Figure 9.13: Trends and Forecast for the Spanish siRNA Drug Market ($B) (2019-2035)
  • Figure 9.14: Trends and Forecast for the Italian siRNA Drug Market ($B) (2019-2035)
  • Figure 9.15: Trends and Forecast for the United Kingdom siRNA Drug Market ($B) (2019-2035)
  • Figure 10.1: Trends and Forecast for the APAC siRNA Drug Market (2019-2035)
  • Figure 10.2: APAC siRNA Drug Market by Delivery Method in 2019, 2026, and 2035
  • Figure 10.3: Trends of the APAC siRNA Drug Market ($B) by Delivery Method (2019-2026)
  • Figure 10.4: Forecast for the APAC siRNA Drug Market ($B) by Delivery Method (2027-2035)
  • Figure 10.5: APAC siRNA Drug Market by Application in 2019, 2026, and 2035
  • Figure 10.6: Trends of the APAC siRNA Drug Market ($B) by Application (2019-2026)
  • Figure 10.7: Forecast for the APAC siRNA Drug Market ($B) by Application (2027-2035)
  • Figure 10.8: APAC siRNA Drug Market by End Use in 2019, 2026, and 2035
  • Figure 10.9: Trends of the APAC siRNA Drug Market ($B) by End Use (2019-2026)
  • Figure 10.10: Forecast for the APAC siRNA Drug Market ($B) by End Use (2027-2035)
  • Figure 10.11: Trends and Forecast for the Japanese siRNA Drug Market ($B) (2019-2035)
  • Figure 10.12: Trends and Forecast for the Indian siRNA Drug Market ($B) (2019-2035)
  • Figure 10.13: Trends and Forecast for the Chinese siRNA Drug Market ($B) (2019-2035)
  • Figure 10.14: Trends and Forecast for the South Korean siRNA Drug Market ($B) (2019-2035)
  • Figure 10.15: Trends and Forecast for the Indonesian siRNA Drug Market ($B) (2019-2035)
  • Figure 11.1: Trends and Forecast for the ROW siRNA Drug Market (2019-2035)
  • Figure 11.2: ROW siRNA Drug Market by Delivery Method in 2019, 2026, and 2035
  • Figure 11.3: Trends of the ROW siRNA Drug Market ($B) by Delivery Method (2019-2026)
  • Figure 11.4: Forecast for the ROW siRNA Drug Market ($B) by Delivery Method (2027-2035)
  • Figure 11.5: ROW siRNA Drug Market by Application in 2019, 2026, and 2035
  • Figure 11.6: Trends of the ROW siRNA Drug Market ($B) by Application (2019-2026)
  • Figure 11.7: Forecast for the ROW siRNA Drug Market ($B) by Application (2027-2035)
  • Figure 11.8: ROW siRNA Drug Market by End Use in 2019, 2026, and 2035
  • Figure 11.9: Trends of the ROW siRNA Drug Market ($B) by End Use (2019-2026)
  • Figure 11.10: Forecast for the ROW siRNA Drug Market ($B) by End Use (2027-2035)
  • Figure 11.11: Trends and Forecast for the Middle Eastern siRNA Drug Market ($B) (2019-2035)
  • Figure 11.12: Trends and Forecast for the South American siRNA Drug Market ($B) (2019-2035)
  • Figure 11.13: Trends and Forecast for the African siRNA Drug Market ($B) (2019-2035)
  • Figure 12.1: Porter's Five Forces Analysis of the Global siRNA Drug Market
  • Figure 12.2: Market Share (%) of Top Players in the Global siRNA Drug Market (2026)
  • Figure 13.1: Growth Opportunities for the Global siRNA Drug Market by Delivery Method
  • Figure 13.2: Growth Opportunities for the Global siRNA Drug Market by Application
  • Figure 13.3: Growth Opportunities for the Global siRNA Drug Market by End Use
  • Figure 13.4: Growth Opportunities for the Global siRNA Drug Market by Region
  • Figure 13.5: Emerging Trends in the Global siRNA Drug Market

List of Tables

  • Table 1.1: Growth Rate (%, 2025-2026) and CAGR (%, 2027-2035) of the siRNA Drug Market by Delivery Method, Application, and End Use
  • Table 1.2: Attractiveness Analysis for the siRNA Drug Market by Region
  • Table 1.3: Global siRNA Drug Market Parameters and Attributes
  • Table 3.1: Trends of the Global siRNA Drug Market (2019-2026)
  • Table 3.2: Forecast for the Global siRNA Drug Market (2027-2035)
  • Table 4.1: Attractiveness Analysis for the Global siRNA Drug Market by Delivery Method
  • Table 4.2: Market Size and CAGR of Various Delivery Method in the Global siRNA Drug Market (2019-2026)
  • Table 4.3: Market Size and CAGR of Various Delivery Method in the Global siRNA Drug Market (2027-2035)
  • Table 4.4: Trends of Nanoparticles in the Global siRNA Drug Market (2019-2026)
  • Table 4.5: Forecast for Nanoparticles in the Global siRNA Drug Market (2027-2035)
  • Table 4.6: Trends of Lipid-based in the Global siRNA Drug Market (2019-2026)
  • Table 4.7: Forecast for Lipid-based in the Global siRNA Drug Market (2027-2035)
  • Table 4.8: Trends of Polymer-based in the Global siRNA Drug Market (2019-2026)
  • Table 4.9: Forecast for Polymer-based in the Global siRNA Drug Market (2027-2035)
  • Table 4.10: Trends of Others in the Global siRNA Drug Market (2019-2026)
  • Table 4.11: Forecast for Others in the Global siRNA Drug Market (2027-2035)
  • Table 5.1: Attractiveness Analysis for the Global siRNA Drug Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global siRNA Drug Market (2019-2026)
  • Table 5.3: Market Size and CAGR of Various Application in the Global siRNA Drug Market (2027-2035)
  • Table 5.4: Trends of Oncology in the Global siRNA Drug Market (2019-2026)
  • Table 5.5: Forecast for Oncology in the Global siRNA Drug Market (2027-2035)
  • Table 5.6: Trends of Cardiovascular in the Global siRNA Drug Market (2019-2026)
  • Table 5.7: Forecast for Cardiovascular in the Global siRNA Drug Market (2027-2035)
  • Table 5.8: Trends of Respiratory in the Global siRNA Drug Market (2019-2026)
  • Table 5.9: Forecast for Respiratory in the Global siRNA Drug Market (2027-2035)
  • Table 5.10: Trends of Neurological in the Global siRNA Drug Market (2019-2026)
  • Table 5.11: Forecast for Neurological in the Global siRNA Drug Market (2027-2035)
  • Table 5.12: Trends of Infectious Diseases in the Global siRNA Drug Market (2019-2026)
  • Table 5.13: Forecast for Infectious Diseases in the Global siRNA Drug Market (2027-2035)
  • Table 5.14: Trends of Others in the Global siRNA Drug Market (2019-2026)
  • Table 5.15: Forecast for Others in the Global siRNA Drug Market (2027-2035)
  • Table 6.1: Attractiveness Analysis for the Global siRNA Drug Market by End Use
  • Table 6.2: Market Size and CAGR of Various End Use in the Global siRNA Drug Market (2019-2026)
  • Table 6.3: Market Size and CAGR of Various End Use in the Global siRNA Drug Market (2027-2035)
  • Table 6.4: Trends of Hospitals in the Global siRNA Drug Market (2019-2026)
  • Table 6.5: Forecast for Hospitals in the Global siRNA Drug Market (2027-2035)
  • Table 6.6: Trends of Research Institutes in the Global siRNA Drug Market (2019-2026)
  • Table 6.7: Forecast for Research Institutes in the Global siRNA Drug Market (2027-2035)
  • Table 6.8: Trends of Pharmaceutical & Biotechnology Companies in the Global siRNA Drug Market (2019-2026)
  • Table 6.9: Forecast for Pharmaceutical & Biotechnology Companies in the Global siRNA Drug Market (2027-2035)
  • Table 6.10: Trends of Others in the Global siRNA Drug Market (2019-2026)
  • Table 6.11: Forecast for Others in the Global siRNA Drug Market (2027-2035)
  • Table 7.1: Market Size and CAGR of Various Regions in the Global siRNA Drug Market (2019-2026)
  • Table 7.2: Market Size and CAGR of Various Regions in the Global siRNA Drug Market (2027-2035)
  • Table 8.1: Trends of the North American siRNA Drug Market (2019-2026)
  • Table 8.2: Forecast for the North American siRNA Drug Market (2027-2035)
  • Table 8.3: Market Size and CAGR of Various Delivery Method in the North American siRNA Drug Market (2019-2026)
  • Table 8.4: Market Size and CAGR of Various Delivery Method in the North American siRNA Drug Market (2027-2035)
  • Table 8.5: Market Size and CAGR of Various Application in the North American siRNA Drug Market (2019-2026)
  • Table 8.6: Market Size and CAGR of Various Application in the North American siRNA Drug Market (2027-2035)
  • Table 8.7: Market Size and CAGR of Various End Use in the North American siRNA Drug Market (2019-2026)
  • Table 8.8: Market Size and CAGR of Various End Use in the North American siRNA Drug Market (2027-2035)
  • Table 8.9: Trends and Forecast for the United States siRNA Drug Market (2019-2035)
  • Table 8.10: Trends and Forecast for the Mexican siRNA Drug Market (2019-2035)
  • Table 8.11: Trends and Forecast for the Canadian siRNA Drug Market (2019-2035)
  • Table 9.1: Trends of the European siRNA Drug Market (2019-2026)
  • Table 9.2: Forecast for the European siRNA Drug Market (2027-2035)
  • Table 9.3: Market Size and CAGR of Various Delivery Method in the European siRNA Drug Market (2019-2026)
  • Table 9.4: Market Size and CAGR of Various Delivery Method in the European siRNA Drug Market (2027-2035)
  • Table 9.5: Market Size and CAGR of Various Application in the European siRNA Drug Market (2019-2026)
  • Table 9.6: Market Size and CAGR of Various Application in the European siRNA Drug Market (2027-2035)
  • Table 9.7: Market Size and CAGR of Various End Use in the European siRNA Drug Market (2019-2026)
  • Table 9.8: Market Size and CAGR of Various End Use in the European siRNA Drug Market (2027-2035)
  • Table 9.9: Trends and Forecast for the German siRNA Drug Market (2019-2035)
  • Table 9.10: Trends and Forecast for the French siRNA Drug Market (2019-2035)
  • Table 9.11: Trends and Forecast for the Spanish siRNA Drug Market (2019-2035)
  • Table 9.12: Trends and Forecast for the Italian siRNA Drug Market (2019-2035)
  • Table 9.13: Trends and Forecast for the United Kingdom siRNA Drug Market (2019-2035)
  • Table 10.1: Trends of the APAC siRNA Drug Market (2019-2026)
  • Table 10.2: Forecast for the APAC siRNA Drug Market (2027-2035)
  • Table 10.3: Market Size and CAGR of Various Delivery Method in the APAC siRNA Drug Market (2019-2026)
  • Table 10.4: Market Size and CAGR of Various Delivery Method in the APAC siRNA Drug Market (2027-2035)
  • Table 10.5: Market Size and CAGR of Various Application in the APAC siRNA Drug Market (2019-2026)
  • Table 10.6: Market Size and CAGR of Various Application in the APAC siRNA Drug Market (2027-2035)
  • Table 10.7: Market Size and CAGR of Various End Use in the APAC siRNA Drug Market (2019-2026)
  • Table 10.8: Market Size and CAGR of Various End Use in the APAC siRNA Drug Market (2027-2035)
  • Table 10.9: Trends and Forecast for the Japanese siRNA Drug Market (2019-2035)
  • Table 10.10: Trends and Forecast for the Indian siRNA Drug Market (2019-2035)
  • Table 10.11: Trends and Forecast for the Chinese siRNA Drug Market (2019-2035)
  • Table 10.12: Trends and Forecast for the South Korean siRNA Drug Market (2019-2035)
  • Table 10.13: Trends and Forecast for the Indonesian siRNA Drug Market (2019-2035)
  • Table 11.1: Trends of the ROW siRNA Drug Market (2019-2026)
  • Table 11.2: Forecast for the ROW siRNA Drug Market (2027-2035)
  • Table 11.3: Market Size and CAGR of Various Delivery Method in the ROW siRNA Drug Market (2019-2026)
  • Table 11.4: Market Size and CAGR of Various Delivery Method in the ROW siRNA Drug Market (2027-2035)
  • Table 11.5: Market Size and CAGR of Various Application in the ROW siRNA Drug Market (2019-2026)
  • Table 11.6: Market Size and CAGR of Various Application in the ROW siRNA Drug Market (2027-2035)
  • Table 11.7: Market Size and CAGR of Various End Use in the ROW siRNA Drug Market (2019-2026)
  • Table 11.8: Market Size and CAGR of Various End Use in the ROW siRNA Drug Market (2027-2035)
  • Table 11.9: Trends and Forecast for the Middle Eastern siRNA Drug Market (2019-2035)
  • Table 11.10: Trends and Forecast for the South American siRNA Drug Market (2019-2035)
  • Table 11.11: Trends and Forecast for the African siRNA Drug Market (2019-2035)
  • Table 12.1: Product Mapping of siRNA Drug Suppliers Based on Segments
  • Table 12.2: Operational Integration of siRNA Drug Manufacturers
  • Table 12.3: Rankings of Suppliers Based on siRNA Drug Revenue
  • Table 13.1: New Product Launches by Major siRNA Drug Producers (2019-2026)
  • Table 13.2: Certification Acquired by Major Competitor in the Global siRNA Drug Market